Gabriel Morris - Dec 15, 2021 Form 3 Insider Report for Immix Biopharma, Inc. (IMMX)

Signature
/s/ Gabriel S Morris
Stock symbol
IMMX
Transactions as of
Dec 15, 2021
Transactions value $
$0
Form type
3
Date filed
12/15/2021, 08:03 PM
Next filing
Dec 20, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMMX Options (right to purchase) Dec 15, 2021 Common stock 257K $0.80 Direct F1
holding IMMX Options (right to purchase) Dec 15, 2021 Common stock 210K $1.86 Direct F2
holding IMMX Warrants (right to purchase) Dec 15, 2021 Common stock 96K $0.80 See footnote F3, F7
holding IMMX Warrants (right to purchase) Dec 15, 2021 Common stock 60K $0.80 See footnote F3, F7
holding IMMX Convertible Note Dec 15, 2021 Common stock See footnote F4, F7
holding IMMX Convertible Note Dec 15, 2021 Common stock See footnote F5, F7
holding IMMX Convertible Note Dec 15, 2021 Common stock Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 12, 2021, the Registrant issued the Reporting Person options to purchase up to 256,500 shares of the Registrant's common stock (the "Options"). The Options vest in 24 monthly installments with the first installment vesting on March 24, 2021, subject to the Reporting Person's continued service with the Registrant. Notwithstanding the foregoing, in the event of the termination of the Management Services Agreement by and between the Registrant and Alwaysraise LLC dated March 24, 2021 (as amended, the "Agreement"), one-half of the Options shall become fully vested. In the event that fewer than one-half of the Options are available to be vested, the remaining portion of the Options subject to vesting shall become fully vested.
F2 On June 18, 2021, the Registrant issued the Reporting Person options to purchase up to 210,000 shares of the Registrant's common stock (the "June Options"). The June Options vest in 48 monthly installments with the first installment vesting on June 18, 2021, subject to the Reporting Person's continued service with the Registrant. Notwithstanding the foregoing, in the event of the termination of the Agreement, one-half of the June Options shall become fully vested. In the event that fewer than one-half of the June Options are available to be vested, the remaining portion of the June Options subject to vesting shall become fully vested.
F3 The warrant is held by Alwaysraise LLC ("Alwaysraise").
F4 On March 18, 2021, the Registrant issued Alwaysraise a note in the amount of $100,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. If the Registrant sells its equity securities prior to such date resulting in proceeds of not less than $10 million ("Qualified Financing"), then the note will automatically convert into such number of equity securities sold in the Qualified Financing at a conversion price equal to the lesser of (i) the price paid per equity security in the Qualified Financing multiplied by 0.80 and (ii) the quotient resulting from dividing $10 million by the number of outstanding shares of common stock immediately prior to the Qualified Financing (assuming the conversion of all securities convertible into common stock and the exercise of all outstanding options and warrants, including shares of common stock reserved and available for future grant under any equity incentive or similar plans).
F5 On April 2, 2021, the Registrant issued Alwaysraise a note in the amount of $100,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. If the Registrant sells its equity securities prior to such date in a Qualified Financing, then the note will automatically convert into such number of equity securities sold in the Qualified Financing at a conversion price equal to the lesser of (i) the price paid per equity security in the Qualified Financing multiplied by 0.80 and (ii) the quotient resulting from dividing $10 million by the number of outstanding shares of common stock immediately prior to the Qualified Financing (assuming the conversion of all securities convertible into common stock and the exercise of all outstanding options and warrants, including shares of common stock reserved and available for future grant under any equity incentive or similar plans).
F6 On March 18, 2021, the Registrant issued the Reporting Person a note in the amount of $60,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. If the Registrant sells its equity securities prior to such date in a Qualified Financing, then the note will automatically convert into such number of equity securities sold in the Qualified Financing at a conversion price equal to the lesser of (i) the price paid per equity security in the Qualified Financing multiplied by 0.80 and (ii) the quotient resulting from dividing $10 million by the number of outstanding shares of common stock immediately prior to the Qualified Financing (assuming the conversion of all securities convertible into common stock and the exercise of all outstanding options and warrants, including shares of common stock reserved and available for future grant under any equity incentive or similar plans).
F7 Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise and in such capacity has the right to vote and dispose of the securities held by such entity.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney